FOR A WORLD WITHOUT AUTOIMMUNE DISEASES
CuraVac's goal is to cure or significantly improve the quality of life of those suffering from autoimmune diseases through a simple and definitive course of treatment: 3 injections of a therapeutic vaccine as an Active Targeted Immunotherapy.

CuraVac is a small clinical stage asset-centric biotech company which manages a network of subcontractors to develop a therapeutic platform.

This extremely flexible organizational model enables CuraVac to limit fixed and infrastructural expenses and to maximize benefits for the patients, society and stakeholders.

FOR A WORLD WITHOUT AUTOIMMUNE DISEASES

A DEFINITIVE CURE

Therapeutic vaccines for autoimmune diseases induce a reprograming and rebalancing of the immune system to stop the autoimmune attack. This innovative approach is based on the Molecular Recognition Theory and the use of complementary peptides, discovered by Professor J. Edwin Blalock (University of Alabama at Birmingham) and CSO of CuraVac. Therapeutic vaccines are centered on the patient and aim to definitively cure; the opposite of long term maintenance therapy.

CuraVac is currently concentrating on myasthenia gravis (MG). The development platform has also proven to be effective in preclinical testing of other autoimmune diseases like MS, GBS, SLE, and can be applied to any autoimmune disease with well identified autoantigens. More than 50 million people in Europe, the USA and Japan alone suffer from autoimmune diseases.
1 500 000 MG PATIENTS

SPEND $7.5 BILLION/YEAR

1 500 000 MS PATIENTS

50 000 000 PATIENTS WITH AUTOIMMUNE DISEASES

80% FINANCED
EUROPEAN UNION FP7 R&D PROGRAM
CuraVac’s first therapeutic vaccine is a treatment for myasthenia gravis, an autoimmune disease that attacks the neuromuscular junction. It causes a specific kind of muscular fatigue and weakness that can become extreme and affect all voluntary muscles including those for vision and respiration.

250,000 people have been diagnosed with myasthenia gravis in the USA, Japan and Europe. The individual patient cost in maintenance therapy is currently $30,000 per year which represents an annual expenditure of $7.5 billion for these markets.

The therapeutic vaccine for myasthenia gravis has been granted orphan drug status in Europe and the USA.

By substituting maintenance therapy with a vaccine cure everyone becomes a winner: the patients - society - stakeholders.

The Myasterix project represents a total budget of €7.5 million over 5 years. It began in 2013 and led to the start of phase 1b on patients at the end of 2015. It is 80% subsidized by the European Commission through the 7th Framework Program of the European Union for research and development technology (FP7).

The phase 1b clinical trial on MG patients is being conducted by the Antwerp University Hospital (UZA) in Belgium in collaboration with the Leiden University Medical Center (LUMC) in the Netherlands. Both institutions are reference centers for MG. Phase 2b in Europe is financed and is expected to fast track the MG therapeutic vaccine to approval by the EMA.
GO FURTHER, FASTER

“At CuraVac, we maximize the use of the funds we raise but above all we reduce to a minimum the risks linked to the development of a revolutionary therapeutic technology. The therapeutic vaccine for myasthenia gravis is a first step which opens doors to other treatments. CuraVac is constantly looking for ways to go further and faster towards our goal of a world without myasthenia gravis, multiple sclerosis, and other autoimmune diseases”

Dr. Stéphane Huberty
CEO of CuraVac
FOR A WORLD WITHOUT AUTOIMMUNE DISEASES

TO BE A PART OF OUR PROJECT OR FOR MORE INFORMATION, CONTACT US:

Dr. Stéphane Huberty, MD
CEO of CuraVac
Nicolas Havelange, 
COO of CuraVac

Avenue de Villefranche 80
B-1330 Rixensart | Belgium
T. +32 2 686 04 45
info@curavac.com
www.curavac.com